

USFDA gives final approval to Bupropion Hydrochloride ER tablets by Jubilant Life Science

10 July 2017 | News

This is the fourth approval the company has received from the USFDA during the current financial year



Jubilant life science has recently announced that it has received Abbreviated New Drug Application (ANDA) final approval for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 150 mg and 300 mg, the generic version of Wellbutrin XL of Valeant, which is used for the treatment of major depressive disorder and prevention of seasonal affective disorder.

This is the fourth approval the company has received from the USFDA during the current financial year.